EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Bringing Innovation in Bioequivalence Studies: Evaluating Multiple Test Formulations in a Single Crossover Pivotal Bioequivalence Study Using Multiplicity Correction

Chandra Teja Uppuluri iD, Rajkumar Boddu iD, Sohel Mohammed Khan iD, Anuj Kumar Saini iD, Sivacharan Kollipara iD

The Journal of Clinical Pharmacology · 2026-11 · 66 (11)

DOI: 10.1002/jcph.70325 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 02.11.2026. Verfasst von Chandra Teja Uppuluri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Tel…. Hauptthemen laut MEDLINE: Research Design, Therapeutic Equivalency. Die Arbeit nennt 15 Literaturangaben. Gefördert von: by Dr. Reddy's Laboratories Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ICH M13A recognizes higher‐order bioequivalence (BE) studies involving multiple test or comparator products. When any one of several test formulations may independently demonstrate BE and support subsequent selection, multiplicity adjustment is required to control the family‐wise type I error rate. This requirement introduces a practical penalty through increased sample‐size requirements, wider confidence intervals, and a narrower range of test‐to‐reference geometric mean ratios that would result in BE conclusions. Although the statistical foundations of multiplicity correction are well established, the available literature has focused predominantly on methodological procedures, with limited consideration of the practical questions encountered during pharmaceutical product development. This review briefly summarizes the regulatory and statistical background and presents a scenario‐based evaluation of the consequences of multiplicity in multi‐formulation crossover BE studies. Analytical assessments were used to quantify sample‐size inflation, confidence interval widening, and contraction of the T/R range that would result in a BE conclusion. Simulated BE study datasets complemented these evaluations, analyzed using full‐data pooled‐MSE (mean squared error) and separate pairwise ANOVA (analysis of variance) approaches and four multiplicity strategies: no adjustment, Bonferroni, Holm, and Hochberg for multiplicity adjustment. The review provides a practical framework for balancing statistical penalty against the value of preserving the ability to retain more than one formulation candidate within a single pivotal study or development. The present evaluation is restricted to non‐replicate crossover BE studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignTherapeutic EquivalencyHumansCross-Over StudiesSample Size

Stichwörter der Autor:innen

ICH M13Abioequivalencecrossover studiesformulation selectionmultiple test formulationsmultiplicity correction

Autor:innen und Institutionen

  • Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.
  • Clinical Pharmacokinetics, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.

ORCID-Profile: Chandra Teja Uppuluri, Rajkumar Boddu, Sohel Mohammed Khan, Anuj Kumar Saini, Sivacharan Kollipara

Förderung

  • by Dr. Reddy's Laboratories Ltd

Zitieren

APA

Uppuluri, C. T., Boddu, R., Khan, S. M., Saini, A. K., & Kollipara, S. (2026). Bringing Innovation in Bioequivalence Studies: Evaluating Multiple Test Formulations in a Single Crossover Pivotal Bioequivalence Study Using Multiplicity Correction. The Journal of Clinical Pharmacology, 66(11). https://doi.org/10.1002/jcph.70325

Vancouver

Uppuluri CT, Boddu R, Khan SM, Saini AK, Kollipara S. Bringing Innovation in Bioequivalence Studies: Evaluating Multiple Test Formulations in a Single Crossover Pivotal Bioequivalence Study Using Multiplicity Correction. The Journal of Clinical Pharmacology. 2026;66(11). doi:10.1002/jcph.70325

BibTeX
@article{Uppuluri2026,
  author = {Uppuluri, Chandra Teja and Boddu, Rajkumar and Khan, Sohel Mohammed and Saini, Anuj Kumar and Kollipara, Sivacharan},
  title = {Bringing Innovation in Bioequivalence Studies: Evaluating Multiple Test Formulations in a Single Crossover Pivotal Bioequivalence Study Using Multiplicity Correction},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {11},
  doi = {10.1002/jcph.70325}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche